Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASNDNASDAQ:ITCINASDAQ:NAMSNASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$172.06+2.7%$155.31$111.09▼$183.00$10.49B0.41494,950 shs1.18 million shsITCIIntra-Cellular Therapies$131.87$131.49$64.09▼$131.98$14.05B0.691.47 million shsN/ANAMSNewAmsterdam Pharma$20.03$19.68$14.06▼$27.29$2.20B-0.01600,952 shs487,846 shsROIVRoivant Sciences$11.48-0.9%$10.42$8.73▼$13.06$8.19B1.255.52 million shs8.77 million shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+2.74%+4.82%+13.09%+31.69%+22.02%ITCIIntra-Cellular Therapies0.00%0.00%-0.03%+3.77%+81.31%NAMSNewAmsterdam Pharma0.00%+14.33%+9.99%-10.14%-8.83%ROIVRoivant Sciences-0.86%+4.27%+13.89%+3.14%+2.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNDAscendis Pharma A/S2.3197 of 5 stars3.52.00.00.02.61.70.6ITCIIntra-Cellular Therapies0.9174 of 5 stars1.10.00.04.51.11.70.6NAMSNewAmsterdam Pharma3.1814 of 5 stars3.53.00.00.03.54.20.0ROIVRoivant Sciences2.2192 of 5 stars3.51.00.00.03.72.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 2.93Moderate Buy$211.4022.86% UpsideITCIIntra-Cellular Therapies 2.17Hold$109.70-16.81% DownsideNAMSNewAmsterdam Pharma 3.00Buy$43.33116.34% UpsideROIVRoivant Sciences 3.00Buy$17.5052.44% UpsideCurrent Analyst Ratings BreakdownLatest NAMS, ITCI, ROIV, and ASND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025ASNDAscendis Pharma A/SRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$205.00 ➝ $210.005/2/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$200.00 ➝ $245.005/2/2025ASNDAscendis Pharma A/SWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$181.00 ➝ $212.005/2/2025ASNDAscendis Pharma A/SEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$260.00 ➝ $280.004/21/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.004/16/2025ASNDAscendis Pharma A/SRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$205.004/8/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.004/2/2025ITCIIntra-Cellular TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$132.00 ➝ $132.003/18/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$168.00 ➝ $200.003/4/2025ROIVRoivant SciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/3/2025NAMSNewAmsterdam PharmaUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$41.00(Data available from 5/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$363.64M28.85N/AN/A($1.88) per share-91.52ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44NAMSNewAmsterdam Pharma$45.56M48.28N/AN/A$3.50 per share5.72ROIVRoivant Sciences$122.59M66.82N/AN/A$7.76 per share1.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$7.10N/A716.92N/A-104.54%N/A-39.23%N/AITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%5/6/2025 (Estimated)NAMSNewAmsterdam Pharma-$176.94M-$2.60N/AN/AN/AN/AN/AN/A5/14/2025 (Estimated)ROIVRoivant Sciences$4.35B-$0.15N/AN/AN/A-119.54%-14.05%-12.81%5/29/2025 (Estimated)Latest NAMS, ITCI, ROIV, and ASND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025ROIVRoivant Sciences-$0.16N/AN/AN/A$62.17 millionN/A5/14/2025Q1 2025NAMSNewAmsterdam Pharma-$0.45N/AN/AN/A$1.46 millionN/A5/1/2025Q1 2025ASNDAscendis Pharma A/S-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 million2/26/2025Q4 2024NAMSNewAmsterdam Pharma-$0.48-$0.95-$0.47-$0.95$3.30 million$12.77 million2/21/2025Q4 2024ITCIIntra-Cellular Therapies-$0.08-$0.16-$0.08-$0.16$205.08 million$199.22 million2/12/2025Q4 2024ASNDAscendis Pharma A/S-$1.32-$0.68+$0.64-$0.68$115.06 millionN/A2/10/2025Q3 2025ROIVRoivant Sciences-$0.24-$0.20+$0.04$0.23$4.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.170.84ITCIIntra-Cellular TherapiesN/A7.667.51NAMSNewAmsterdam PharmaN/A10.6110.61ROIVRoivant SciencesN/A37.9137.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/AITCIIntra-Cellular Therapies92.33%NAMSNewAmsterdam Pharma89.89%ROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%ITCIIntra-Cellular Therapies2.60%NAMSNewAmsterdam Pharma19.50%ROIVRoivant Sciences7.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S64060.97 million36.41 millionOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableNAMSNewAmsterdam Pharma4109.82 million74.37 millionOptionableROIVRoivant Sciences860713.55 million657.18 millionOptionableNAMS, ITCI, ROIV, and ASND HeadlinesRecent News About These CompaniesRoivant Sciences (NASDAQ:ROIV) Hits New 52-Week High - Time to Buy?May 3 at 4:30 AM | marketbeat.comRoivant Sciences Ltd. (ROIV): Among David Einhorn’s Stock Picks with Huge Upside PotentialMay 2 at 11:46 AM | insidermonkey.comRoivant Sciences Ltd. (ROIV): Among David Einhorn’s Stock Picks with Huge Upside PotentialMay 2 at 11:02 AM | msn.comRoivant Sciences Ltd. (NASDAQ:ROIV) Shares Acquired by PDT Partners LLCMay 1 at 8:19 AM | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Position Boosted by TOMS Capital Investment Management LPMay 1 at 8:11 AM | marketbeat.comRoivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside PotentialApril 29, 2025 | insidermonkey.comIntegrated Wealth Concepts LLC Purchases 41,564 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)April 29, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Position Increased by Tower Research Capital LLC TRCApril 29, 2025 | marketbeat.comGilder Gagnon Howe & Co. LLC Acquires Shares of 1,162,986 Roivant Sciences Ltd. (NASDAQ:ROIV)April 28, 2025 | marketbeat.comSyon Capital LLC Buys Shares of 22,814 Roivant Sciences Ltd. (NASDAQ:ROIV)April 28, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by First Trust Advisors LPApril 28, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Holdings Increased by Two Seas Capital LPApril 27, 2025 | marketbeat.comBarclays PLC Buys 110,371 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)April 27, 2025 | marketbeat.comCredit Industriel ET Commercial Invests $1.77 Million in Roivant Sciences Ltd. (NASDAQ:ROIV)April 26, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Stock Holdings Lessened by Adage Capital Partners GP L.L.C.April 26, 2025 | marketbeat.comInsider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 100,000 Shares of StockApril 24, 2025 | marketbeat.comBlackBarn Capital Partners LP Increases Stock Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)April 24, 2025 | marketbeat.comPeak6 LLC Invests $355,000 in Roivant Sciences Ltd. (NASDAQ:ROIV)April 24, 2025 | marketbeat.comCantor Fitzgerald maintains overweight on Roivant Sciences stockApril 23, 2025 | uk.investing.comRoivant Sciences (NASDAQ:ROIV) Receives "Buy" Rating from HC WainwrightApril 23, 2025 | marketbeat.comRoivant Sciences: Primed For Growth With A De-Risked PipelineApril 23, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNAMS, ITCI, ROIV, and ASND Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$172.06 +4.59 (+2.74%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$172.00 -0.06 (-0.03%) As of 05/2/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Intra-Cellular Therapies NASDAQ:ITCI$131.87 0.00 (0.00%) As of 04/2/2025Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.NewAmsterdam Pharma NASDAQ:NAMS$20.03 0.00 (0.00%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$20.02 -0.01 (-0.02%) As of 05/2/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Roivant Sciences NASDAQ:ROIV$11.48 -0.10 (-0.86%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$11.44 -0.04 (-0.30%) As of 05/2/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/28 - 05/02 Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Is It Time to Load Up on Bond ETFs? Palantir Earnings: 1 Bullish Signal and 1 Area of Concern Roblox Stock Gains Momentum and Can Top $100 in 2025 Microsoft Crushes Earnings, What’s Next for MSFT Stock? 3 Biotech Giants Gaining From U.S. Sales and Policy Shifts Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
